Source comparison
PT-141 vs Other Research Peptides: Full Comparison
PT-141 Melanocortin receptor agonist MC3R, MC4R (hypothalamus) 2.7 hours Sexual arousal pathways, reward signaling, melanocortin system studies Unique CNS-focused mechanism with no overlap in metabolic, anabolic, or regenerative domains Semaglutide GLP-1 recep
This comparison does not assign a generated winner or score.
- PT-141
- Melanocortin receptor agonist
- MC3R, MC4R (hypothalamus)
- 2.7 hours
- Sexual arousal pathways, reward signaling, melanocortin system studies
- Unique CNS-focused mechanism with no overlap in metabolic, anabolic, or regenerative domains
- Semaglutide
- GLP-1 receptor agonist
- GLP-1R (gut, pancreas, hypothalamus)
- 7 days
- Glucose metabolism, appetite regulation, insulin sensitivity
- Entirely different pathway. Targets incretin system, not melanocortin receptors
- CJC-1295
- Growth hormone secretagogue
- GHSR1a (pituitary gland)
- 6–8 days (with DAC)
- Growth hormone release, anabolic signaling, IGF-1 upregulation
- No shared mechanism with PT-141. Operates via ghrelin receptor, not melanocortin
- BPC-157
- Tissue repair and angiogenesis
- VEGF pathway, nitric oxide modulation
- 4 hours (estimated)
- Wound healing, tendon repair, gastrointestinal protection
- Zero overlap with PT-141. Acts on injury sites and vascular growth, not CNS arousal
- TB-500
- Actin-binding peptide
- Cytoskeletal actin filaments
- 10 days
- Cell migration, angiogenesis, collagen deposition
- Structural healing peptide with no CNS or melanocortin activity
- Ipamorelin
- 2 hours
- Selective GH release without cortisol or prolactin elevation
- Short half-life similar to PT-141 but entirely different hormonal axis